Ermenegildo Zegna NV
ZGN
DexCom
DXCM
New Fortress Energy
NFE
Workday
WDAY
eBay
EBAY
US Stock MarketDetailed Quotes
ENVB Enveric Biosciences
- 0.3250
- -0.0034-1.04%
Close Dec 20 16:00 ET
- 0.3294
- +0.0044+1.35%
Post 20:01 ET
3.23MMarket Cap-0.13P/E (TTM)
0.3366High0.3130Low202.11KVolume0.3143Open0.3284Pre Close65.65KTurnover2.16%Turnover RatioLossP/E (Static)9.94MShares2.920052wk High0.82P/B3.05MFloat Cap0.303652wk Low--Dividend TTM9.38MShs Float67500.0000Historical High--Div YieldTTM7.19%Amplitude0.3036Historical Low0.3240Avg Price1Lot Size
Enveric Biosciences Stock Forum
Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds
New patents provide additional composition of matter and methods of use claims for Enveric’s EVM301 series neuroplastogenic molecules, and recently out-licensed tryptamine-derived prodrugs, including EB-002, a new chemical entity psilocin prodrug
Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior
Dose-proportional oral bioavailability without clinical signs, including those associated with hallucinogenic compounds, was demonstrated in rat and dog pharmacokinetic (PK) studies while significant brain penetration was observed in rat
Enveric Biosciences, Inc. (NASDAQ:ENVB) ("Enver...
Enveric Biosciences Preclinical Pharmacokinetic Studies of Eb-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-Like Behavior
Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002
Enveric Biosciences (NASDAQ: ENVB)has signed a licensing agreement with MycoMedica Life Sciences for its EVM201 program, including drug candidate EB-002, a synthetic prodrug for treating neuropsychiatric disorders. The agreement includes potential milestone payments up to $62 million plus tiered single-digit royalties on future sales. MycoMedica receives exclusive globa...
Benzinga· 4 mins ago
Lykos Therapeutics, whose lead asset, midomafetamine capsules (MDMA), failed to win the FDA nod in August, said that the regulator has indicated a path forward for the Ecstasy-based drug, which, if approved, could have been the first psychedelic-assisted therapy.
Midomafetamine, based on the mind-altering drug MDMA, commonly known as Ecstasy or Molly, was rejected by the FDA in August for the treatment of post-traumatic stress disorder...
No comment yet